<DOC>
	<DOCNO>NCT02849886</DOCNO>
	<brief_summary>This study evaluate frequency occurrence , severity , response treatment chemical agent , notably dimerizer AP1903 ( Bellicum Pharmaceuticals compagny ) , case acute Graft versus Host Disease ( aGvHD ) occur administration T-lymphocytes express iCASP9 concomitantly bone marrow graft deplete B- T-lymphocytes</brief_summary>
	<brief_title>T Lymphocytes ( LT ) Expressing iCASP9 ΔCD19 Allogeneic Haematopoietic Transplantation .</brief_title>
	<detailed_description>Haematopoietic transplantation may result serious complication , notably graft versus host disease ( GvHD ) . T-lymphocyte depletion bone marrow graft able prevent GvHD , increase risk rejection reduce antileukaemic effect graft ( graft versus leukaemia , GvL ) . In previous study , investigator show ex vivo transfer Herpes simplex thymidine kinase suicide gene ( HSV-TK ) graft 's T lymphocytes prior reinjection associate immediate toxicity , allow prolonged recirculation genetically modify cell ( GMC ) control induce GvHD ganciclovir ( GCV ) . In addition , study reveal existence GMC resistant GCV , immunodeficiency transduce cell , well increase risk Epstein-Barr virus ( EBV ) -induced lymphoproliferative disease . To overcome difficulty , investigator improve methodology produce GMC use new vector ( pMSCV-iCASP9-2A-ΔCD19 ) whose susceptibility gene human origin associate human surface marker ( non-functional ) enable cell selection process . Moreover , demonstration induce GvHD setting could control administration GCV alone lead significantly increase number genetically modify T-lymphocytes administer omit cyclosporin prophylaxis GvHD . This phase I study include 12 patient conduct accord dose escalation method ( 2.10e6 , 5.10e6 10.10e6 GMC / kg respectively level I , II &amp; III ) . GMC prepare Cell Tissue Engineering Laboratory ( advanced therapy medicinal product departement ) french Blood center ( EFS ) Besançon , France , send transplantation department .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Adult patient age ≤55 year ( 40 &lt; age ≤55 year ) ; Patients candidate myeloablative allogeneic bone marrow transplant : de novo secondary acute lymphoblastic leukaemia ( ALL ) acute myeloblastic leukaemia ( AML ) complete remission ( CR ) ≥1 ; chronic myeloid leukaemia ( CML ) chronic phase escape tyrosine kinase inhibitor ; myelodysplastic syndrome ( MDS ) int2 high International Prognostic Scoring System ( IPSS score , medullary blastosis &gt; 10 % ) ; chemosensitive malignant nonHodgkin 's lymphoma ( MNHL ) CR partial remission ( PR ) &gt; 2 ; chemosensitive Hodgkin 's disease CR PR &gt; 2 ; chemosensitive chronic lymphoid leukaemia ( CLL ) CR PR &gt; 2 ; chemosensitive myeloma CR PR ≥2 ; At high risk GvHD : risk GvHD consider high patient thus eligible study , receiver &gt; 40 year , donor woman receiver man , regardless age ; Karnofsky index &gt; 70 % World Health Organization ( WHO ) index ≥2 ; Stable clinical condition life expectancy &gt; 3 month ; Absence organic disease contraindicate transplantation Availability genotypically identical donor , age &gt; 18 year , give consent , present contraindication bone marrow donation general anaesthesia require apheresis procedure ; Written inform consent donor patient . Age &lt; 40 year &gt; 55 year Organic disease contraindicate utilisation myeloablative conditioning History allogeneic Hematological Stem Cell Transplantation ( HSCT ) ; History autologous HSCT &lt; 1 year prior date schedule allogeneic HSCT ; Neurological location haemopathy justify transplantation ; Pregnant breastfeed woman ; Positive HIV serology ; Positive hepatitis B hepatitis C serology ( except postvaccinal hepatitis B status ) ; Absence inform consent receiver donor ; Inability adhere protocol instruction .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>GvHD</keyword>
	<keyword>Suicide gene</keyword>
	<keyword>Dimerizer drug AP1903</keyword>
	<keyword>Hematological stem cell transplantation</keyword>
</DOC>